Evidence map›Paper›PMID 33898740›Full record

ArticleNeurology. Genetics2021

Interactive Effects of HLA and GM Alleles on the Development of Alzheimer Disease.

Janardan P Pandey, Paul J Nietert, Ronald T Kothera, Lisa L Barnes, David A Bennett

Abstract read
In one paragraph

Article in Neurology. Genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Janardan P PandeyDepartment of Microbiology and Immunology (J.P.P., R.T.K.) and Department of Public Health, Sciences (P.J.N.), Medical University of South Carolina, Charleston; and Rush Alzheimer's Disease Center (L.L.B., D.A.B.), Rush University Medical Center, Chicago, IL.ORCID 0000-0001-9992-4737
Paul J NietertDepartment of Microbiology and Immunology (J.P.P., R.T.K.) and Department of Public Health, Sciences (P.J.N.), Medical University of South Carolina, Charleston; and Rush Alzheimer's Disease Center (L.L.B., D.A.B.), Rush University Medical Center, Chicago, IL.
Ronald T KotheraDepartment of Microbiology and Immunology (J.P.P., R.T.K.) and Department of Public Health, Sciences (P.J.N.), Medical University of South Carolina, Charleston; and Rush Alzheimer's Disease Center (L.L.B., D.A.B.), Rush University Medical Center, Chicago, IL.
Lisa L BarnesDepartment of Microbiology and Immunology (J.P.P., R.T.K.) and Department of Public Health, Sciences (P.J.N.), Medical University of South Carolina, Charleston; and Rush Alzheimer's Disease Center (L.L.B., D.A.B.), Rush University Medical Center, Chicago, IL.
David A BennettDepartment of Microbiology and Immunology (J.P.P., R.T.K.) and Department of Public Health, Sciences (P.J.N.), Medical University of South Carolina, Charleston; and Rush Alzheimer's Disease Center (L.L.B., D.A.B.), Rush University Medical Center, Chicago, IL.

Funding

SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI LEURGANS, SUE E. · 1991 to 2020
$49.1M
EPIDEMIOLOGY OF NEURAL RESERVE AND NEUROBIOLOGY IN AGINGR01AG017917 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2001 to 2023
$43.3M
South Carolina Clinical & Translational Research Institute (SCTR)UL1TR001450 · NCATS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T., FLUME, PATRICK A · 2015 to 2024
$41.1M
RISK FACTORS, PATHOLOGY, AND CLINICAL EXPRESSIONS OF ADR01AG015819 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1998 to 2024
$21.4M
Risk Factors for Cognitive Decline in African-AmericansR01AG022018 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BARNES, LISA L · 2004 to 2025
$18.2M
Genetic Markers of IgG and Cytomegalovirus Immunoevasion in Alzheimer DiseaseR21AG058489 · NIA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI PANDEY, JANARDAN P · 2017 to 2018
$575k
NCATS NIH HHS UL1 TR001450NIA NIH HHS P30 AG010161NIA NIH HHS R01 AG015819NIA NIH HHS R01 AG017917NIA NIH HHS R01 AG022018NIA NIH HHS R21 AG058489
6 · The paper itself

Abstract

objectiveWe investigated whether particular immunoglobulin GM (γ marker) alleles-individually or epistatically with a known human leukocyte antigen (HLA) risk allele-were associated with the development of Alzheimer disease (AD).

methodsUsing a prospective cohort study design, we genotyped DNA samples from 209 African American (AA) and 638 European American (EA) participants for IgG1 (GM 3 and GM 17), IgG2 (GM 23+ and GM 23-), and

resultsIn EA subjects, none of the GM or HLA alleles-individually or epistatically-were associated with time to development of AD. In AA subjects, GM and HLA alleles individually were not associated with time to development of AD. However, there was a significant interaction: In the presence of GM 3 (i.e., GM 3/3 and GM 3/17 subjects), the presence of the HLA-C allele was associated with a 4-fold increase in the likelihood of developing AD compared with its absence (hazard ratio [HR] 4.17, 95% CI, 1.28-13.58). In the absence of GM 3 (GM 17/17 subjects), however, the presence of the HLA-C allele was not associated with time to development of AD (HR 1.10, 95% CI, 0.50-2.41).

conclusionsThese results show that particular GM and HLA alleles epistatically contribute to the development of AD.

Identifiers

PMID33898740
PMCPMC8063623

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.